Compare DRH & BHVN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | DRH | BHVN |
|---|---|---|
| Founded | 2004 | 2013 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Real Estate Investment Trusts | Biotechnology: Pharmaceutical Preparations |
| Sector | Real Estate | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 2.5B | 2.3B |
| IPO Year | 2004 | 2022 |
| Metric | DRH | BHVN |
|---|---|---|
| Price | $12.32 | $13.35 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 10 | 14 |
| Target Price | $10.38 | ★ $29.08 |
| AVG Volume (30 Days) | 2.3M | ★ 3.4M |
| Earning Date | 04-30-2026 | 05-11-2026 |
| Dividend Yield | ★ 3.51% | N/A |
| EPS Growth | ★ 144.44 | 26.08 |
| EPS | ★ 0.51 | N/A |
| Revenue | ★ $1,120,491,000.00 | N/A |
| Revenue This Year | $3.44 | N/A |
| Revenue Next Year | $2.42 | N/A |
| P/E Ratio | $24.25 | ★ N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $7.48 | $7.48 |
| 52 Week High | $13.79 | $18.57 |
| Indicator | DRH | BHVN |
|---|---|---|
| Relative Strength Index (RSI) | 49.74 | 36.40 |
| Support Level | $11.80 | $8.75 |
| Resistance Level | $12.54 | $13.54 |
| Average True Range (ATR) | 0.29 | 0.99 |
| MACD | 0.01 | -0.39 |
| Stochastic Oscillator | 55.98 | 6.09 |
Diamondrock Hospitality Company is a real estate investment trust that owns lodging properties. Its business is to acquire, own, manage, and renovate full-service hotel properties in the United States. It operates in cities such as Chicago, Boston, New York, Denver, and others. Within DiamondRock's holdings, the majority of the hotel brands include Marriott, Starwood, and Hilton. The company operates in one reportable segment: The hotel ownership segment, which is comprised of upper upscale and luxury chain scale hotels that offer hotel rooms, food and beverage and other ancillary guest services.
Biohaven Ltd is a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of life-changing treatments in key therapeutic areas, including immunology, neuroscience, and oncology. Its product pipeline includes Glutamate, Myostatin, Ion channels, Inflammation & Immunology, and Oncology. The company's products target diseases such as neuromuscular and metabolic diseases, antibody-drug conjugates for cancer, obsessive-compulsive disorder and others. Its pipeline products include: BHV-2000, BHV-7000, BHV-2100, BHV-8000, BHV-1310, BHV-1300, BHV-1400, BHV-1600, BHV-1530, and BHV-1500.